2015 Compounding Pharmaceutical Companies 
pharmaphorum
JUNE 12, 2025
Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
European Pharmaceutical Review
OCTOBER 7, 2022
billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Large CMOs held the biggest share of revenue in 2021, as even from the initial stages of drug production, pharmaceutical firms decided to outsource the work to these organisations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 9, 2022
According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015. Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3%
European Pharmaceutical Review
DECEMBER 21, 2022
Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. In 2015 he joined the Process Chemistry & Catalysis group at F.
European Pharmaceutical Review
SEPTEMBER 25, 2023
NMR relaxation methods distinguish between components (phases or compounds) that have different molecular mobilities For monoclonal antibodies, identification methodologies can employ chromatography, spectroscopy, isoelectric focusing, capillary electrophoresis and peptide mapping techniques. 2015; 35(3): 77-79. Chromatography.
Pharmaceutical Technology
OCTOBER 25, 2022
Pharmaceutical companies – and the FDA – are embracing FDCs. Between 2010 and the end of 2015, of the 655 New Drug Applications (NDAs) approved by the FDA, 63 were for FDCs. The potential to extend the patent life and market exclusivity of a company’s APIs is a potent financial incentive. The numbers tell the story.
ISPE
MARCH 6, 2023
link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceutical companies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceutical companies, purchased goods (e.g.,
Expert insights. Personalized for you.
59 
Let's personalize your content